Navigation Links
Factor Bioscience Granted First U.S. Patent for RNA-Based Reprogramming Technology
Date:7/31/2013

CAMBRIDGE, Mass., July 31, 2013 /PRNewswire/ -- The United States Patent and Trademark Office today granted Factor Bioscience the first patent covering methods for reprogramming cells using RNA, a technology with wide-ranging applications in biological research and personalized medicine. The patented methods can transform patient skin cells into stem cells more rapidly, efficiently, and safely than previous techniques.

"Reprogramming is an amazing process, when it works," explains co-inventor Dr. Christopher Rohde, Chief Operating Officer and Director of High-Throughput Technologies. "However, previous methods were burdened by cumbersome protocols, poor reliability, and woeful inefficiency. Our RNA-reprogramming technology overcomes all of these limitations while being faster and safer than the best available techniques."

Excitement has been growing in the reprogramming field since Dr. Shinya Yamanaka's Nobel Prize-winning discovery in 2006 that infecting skin cells with a specific combination of viruses could reprogram them to a pluripotent stem-cell state. However, efforts to achieve the same goal without using the potentially mutation-causing viruses had, until this point, yielded mixed results. "Many researchers have attempted to develop a reliable DNA-free reprogramming method, and more than one have claimed success," says co-inventor Dr. Matt Angel, CEO. "In every case, the reported method turned out to be unreliable at best, and more often than not, completely irreproducible. The grant of the first patent covering reliable DNA-free reprogramming technology brings us one step closer to the development of therapeutics based on safely reprogrammed cells."

The methods developed by Dr. Angel's team can be used with a wide range of reprogramming factors and cell types, and the company is making chemically-defined, animal component-free versions of its products available for therapeutic applications. Dr. Angel's goal is to deploy the technology as widely as possible through a combination of products, services, and partnerships. "Factor Bioscience is a unique company, owned and operated entirely by scientists. The development of the first reliable RNA-reprogramming technology is the perfect example of what is possible in this environment."

About Factor Bioscience
Founded in 2011, Factor Bioscience develops nucleic-acid and cell-based research tools and therapeutics using its patented and patent-pending reprogramming and gene-editing technologies. For more information, visit www.factorbio.com, and follow us on Twitter at @factorbio.

The content of this press release is the sole responsibility of the authors and does not necessarily represent the official views of the USPTO.


'/>"/>
SOURCE Factor Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Elsevier Announces 2012 Journal Impact Factor Highlights
2. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
3. Latest Cell Publication of OriGene and Peking University Collaborative Discovery of New iPSC Reprogramming Factors
4. New study identifies the role of a key growth factor in promoting formation of hair follicles and suggests a new therapeutic approach to treat baldness
5. Cell Culture Market (Media, Sera, Reagents, Serum-Free Media, Albumin, Growth Factors & Cytokines, Instruments, Bioreactors, Roller Bottle Equipment, T-Flasks And Cryostorage Equipment) - Global Industry Analysis, Size, Share, Growth, Trends And For
6. Researchers identify transcription factors that regulate retinal vascularization
7. ChemAxon Provides Chemistry Informatics Platform for the European Lead Factory
8. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
9. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
10. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
11. The X factor in liver metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016 - New FDA action date of ... New FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast ... decade indicated for the treatment of signs and symptoms of dry ... the potential to be the only product approved in the U.S. in the past decade ...
(Date:2/4/2016)... , Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... commercializing its flagship CytoSorb® blood filter to treat ... around the world, announced that CEO Dr. ... the Source Capital Group,s 2016 Disruptive Growth & ... the company.  Conference Presentation Details: ...
(Date:2/4/2016)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... China , today announced that the ... February 4, 2016 a preliminary non-binding proposal letter, dated ... V-Ming ( Shanghai ) Investment Holdings Co., ... Shenzhen ) Fund Management Co., Ltd., Beijing ...
(Date:2/3/2016)... , Feb. 3, 2016  Discovery Laboratories, Inc. ... on developing aerosolized KL4 surfactant therapies for respiratory ... has approved an inducement award as a component ... its newly appointed President and Chief Executive Officer.  ... Committee on February 1, 2016 and granted as ...
Breaking Biology Technology:
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., a ... simplifies the use and access of ubiquitous on-premise ... partnership with American Cyber.  ... experience leading transformational C4ISR and Cyber initiatives in ... the latest proven technology solutions," said Steve ...
(Date:1/11/2016)... Jan. 11, 2016 Synaptics Incorporated (NASDAQ: ... today announced that its ClearPad ® TouchView ™ ... won two separate categories in the 8 th ... Best Technology Breakthrough. The Synaptics ® TDDI solution ... supply chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):